EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients

Marcus Vetter iD, Karin M Rothgiesser, Qiyu Li, Hanne Hawle, Wolfgang Schönfeld, Karin Ribi, Salome Riniker, Roger von Moos, Andreas Trojan, Elena Kralidis, Mathias Fehr, Andreas Müller und 2 weitere

Endocrine Oncology · 2022

DOI: 10.1530/eo-21-0009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine Oncology, 2022. Verfasst von Marcus Vetter und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, University Hospital Basel, Basel, Switzerland. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

CR1447, a novel transdermal formulation of 4-hydroxytestosterone, has aromatase-inhibiting and androgen receptor (AR)-modulating properties (IC 50 4.4 nM) with antitumor effects against AR-positive tumor cells in vitro. This trial investigated the efficacy and safety of CR1447 for patients with metastatic estrogen receptor-positive (A) and AR-positive triple-negative breast cancers (B). Design and methods (A) included patients with at most one prior endocrine therapy line without progression ≥6 months, whereas (B) included patients with ≤2 prior chemotherapy lines, all displaying advanced signs of disease. The primary endpoint was disease control at week 24 (DC24). The null hypothesis was DC24 ≤30% (A) and ≤15% (B). Thirty-seven patients were recruited (29 in (A) and 8 in (B)); accrual was stopped following an interim analysis demonstrating futility in (A) and slow accrual in (B).

Results

DC24 was attained in 5/21 (95% CI: 8.2–47.2) patients in (A) and none in (B). The median progression-free survival was 5.1 months (95% CI: 2.5–5.6) in (A) and 2.5 months (95% CI: 0.7–2.6) in (B). The median overall survival was 24.6 months (95% CI: 22.9–not applicable) in (A) and 10.8 months (95% CI: 3.3–10.9) in (B). CR1447 had a favorable safety profile without treatment-related grade 3–5 toxicities in (A). Especially no side effects linked to androgenic effects were observed.

Conclusions

Despite this trial being negative, the 24% DC24 rate in a second-line setting, and the prolonged partial response experienced by a patient, indicate activity. Further evaluation of CR1447 in endocrine-sensitive patients or combination trials appears warranted.

Schlagwörter

Stichwörter der Autor:innen

CR1447androgen receptorendocrine therapyestrogen receptormetastatic breast cancer

Autor:innen und Institutionen

  • Medical Oncology, University Hospital Basel, Basel, Switzerland.
  • Medical Oncology, Hematology and Immunotherapy, Cantonal Hospital Baselland, Medical University Clinic, Liestal, Switzerland.
  • Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland.
  • CURADIS GmbH, Erlangen, Germany.
  • IBCSG, International Breast Cancer Study Group, Bern, Switzerland.
  • Breast Cancer Center, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

ORCID-Profile: Marcus Vetter

Zitieren

APA

Vetter, M., Rothgiesser, K. M., Li, Q., Hawle, H., Schönfeld, W., Ribi, K., Riniker, S., von Moos, R., Trojan, A., Kralidis, E., Fehr, M., Müller, A., Thürlimann, B., & Swiss Group for Clinical Cancer Research (SAKK) (2022). SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients. Endocrine Oncology. https://doi.org/10.1530/eo-21-0009

Vancouver

Vetter M, Rothgiesser KM, Li Q, Hawle H, Schönfeld W, Ribi K, et al. SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients. Endocrine Oncology. 2022. doi:10.1530/eo-21-0009

BibTeX
@article{Vetter2022,
  author = {Vetter, Marcus and Rothgiesser, Karin M and Li, Qiyu and Hawle, Hanne and Schönfeld, Wolfgang and Ribi, Karin and Riniker, Salome and von Moos, Roger and Trojan, Andreas and Kralidis, Elena and Fehr, Mathias and Müller, Andreas and Thürlimann, Beat and Swiss Group for Clinical Cancer Research (SAKK), Swiss Group for Clinical Cancer Research (SAKK)},
  title = {SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients},
  journal = {Endocrine Oncology},
  year = {2022},
  doi = {10.1530/eo-21-0009}
}
Kostenlos starten →